"Antibody Specificity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
| Descriptor ID |
D000918
|
| MeSH Number(s) |
G12.100
|
| Concept/Terms |
Antibody Specificity- Antibody Specificity
- Antibody Specificities
- Specificities, Antibody
- Specificity, Antibody
|
Below are MeSH descriptors whose meaning is more general than "Antibody Specificity".
Below are MeSH descriptors whose meaning is more specific than "Antibody Specificity".
This graph shows the total number of publications written about "Antibody Specificity" by people in this website by year, and whether "Antibody Specificity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2017 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibody Specificity" by people in Profiles.
-
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Sci Rep. 2020 02 07; 10(1):2093.
-
Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020 01 06; 94(2).
-
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
-
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
-
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
-
Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol. 2015 Jul-Aug; 33(4 Suppl 91):S131-5.
-
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency. J Virol. 2015 May; 89(10):5264-75.
-
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226.
-
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
-
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.